Netherlands· NL-4f11e8721fd9
Menveo, oplossing voor injectie
A meningokokken a, c, y, w-135, tetravalent, gereinigtes polysaccharid-antigen, konjugiert product, registered in Netherlands by GlaxoSmithKline Vaccines S.r.l.. The same ATC class is registered in 11 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Meningokokken a, c, y, w-135, tetravalent, gereinigtes polysaccharid-antigen, konjugiert is registered in 11 of 19 countries.
Countries holding a registration under ATC J07AH08 (meningokokken a, c, y, w-135, tetravalent, gereinigtes polysaccharid-antigen, konjugiert), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 7 of them publish a price we can compare per daily dose
Meningokokken a, c, y, w-135, tetravalent, gereinigtes polysaccharid-antigen, konjugiert · ATC J07AH08
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
CBG-MEB (Netherlands)- Manufacturer
- GlaxoSmithKline Vaccines S.r.l.
- Country
- Netherlands (NL)
- ATC code
- J07AH08
- ATC class
- Meningokokken A, C, Y, W-135, tetravalent, gereinigtes Polysaccharid-Antigen, konjugiert
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/10/614
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under J07AH08
Meningokokken a, c, y, w-135, tetravalent, gereinigtes polysaccharid-antigen, konjugiert, as other registers publish it.
- CanadaMENACTRASANOFI PASTEUR LIMITED
- FinlandMenQuadfiSanofi Winthrop Industrie
- PolandMenQuadfiSanofi Winthrop Industrie
- BelgiumMenQuadfiSanofi Winthrop Industrie
- IcelandMenQuadfiSanofi Winthrop Industrie
- DenmarkMenQuadfiSanofi Winthrop Industrie
- CzechiaMENQUADFISanofi Winthrop Industrie, Gentilly
- CzechiaMENQUADFISanofi Winthrop Industrie, Gentilly
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/eec6402e-181e-4f97-a450-cda7a667f90d GET /v1/drugs/eec6402e-181e-4f97-a450-cda7a667f90d?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Oplossing voor injectie",
"route": "Intramusculair gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/menveo-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Meningococcus A, C, Y, W-135, tetravalent purified polysaccharides antigen conjugated",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp131686",
"excipients": [
"DINATRIUMWATERSTOFFOSFAAT 2-WATER (E 339)",
"NATRIUMCHLORIDE",
"NATRIUMDIWATERSTOFFOSFAAT 1-WATER (E 339)",
"WATER VOOR INJECTIE"
],
"substances": [
"MENINGOKOKKEN OLIGOSACCHARIDE, SEROGROEP A GECONJUGEERD AAN C. DIFTERIE CRM197 CARRIERPROTEÏNE",
"MENINGOKOKKEN OLIGOSACCHARIDE, SEROGROEP C GECONJUGEERD AAN C. DIFTERIE CRM197 CARRIERPROTEÏNE",
"MENINGOKOKKEN OLIGOSACCHARIDE, SEROGROEP W135 GECONJUGEERD AAN C. DIFTERIE CRM197 CARRIERPROTEÏNE",
"MENINGOKOKKEN OLIGOSACCHARIDE, SEROGROEP Y GECONJUGEERD AAN C. DIFTERIE CRM197 CARRIERPROTEÏNE"
],
"leaflet_url": null,
"authorised_at": "2024/09/19",
"procedure_number": "EMEA/H/C/001095",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/10/614",
"additional_monitoring": "N"
}See everything about meningokokken a, c, y, w-135, tetravalent, gereinigtes polysaccharid-antigen, konjugiert.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.